A detailed history of China Universal Asset Management Co., Ltd. transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 13,094 shares of AMLX stock, worth $69,267. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,094
Previous 7,990 63.88%
Holding current value
$69,267
Previous $15,000 180.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$1.65 - $3.24 $8,421 - $16,536
5,104 Added 63.88%
13,094 $42,000
Q2 2024

Jul 19, 2024

SELL
$1.62 - $2.71 $8,122 - $13,587
-5,014 Reduced 38.56%
7,990 $15,000
Q1 2024

Apr 29, 2024

BUY
$2.71 - $19.57 $14,062 - $101,548
5,189 Added 66.4%
13,004 $37,000
Q4 2023

May 21, 2024

SELL
$12.07 - $18.46 $62,631 - $95,788
-5,189 Reduced 39.9%
7,815 $115,000
Q4 2023

Jan 23, 2024

BUY
$12.07 - $18.46 $73,445 - $112,329
6,085 Added 351.73%
7,815 $115,000
Q3 2023

May 21, 2024

BUY
$18.08 - $23.45 $15,367 - $19,932
850 Added 96.59%
1,730 $31,000
Q3 2023

Oct 30, 2023

BUY
$18.08 - $23.45 $15,367 - $19,932
850 Added 96.59%
1,730 $32,000
Q2 2023

May 21, 2024

SELL
$20.98 - $31.42 $356 - $534
-17 Reduced 1.9%
880 $18,000
Q2 2023

Jul 27, 2023

SELL
$20.98 - $31.42 $356 - $534
-17 Reduced 1.9%
880 $19,000
Q1 2023

May 21, 2024

BUY
$27.71 - $40.93 $6,207 - $9,168
224 Added 33.28%
897 $26,000
Q1 2023

Apr 27, 2023

BUY
$27.71 - $40.93 $6,207 - $9,168
224 Added 33.28%
897 $26,000
Q4 2022

May 21, 2024

SELL
$29.75 - $39.26 $366,847 - $484,115
-12,331 Reduced 94.82%
673 $24,000
Q4 2022

Jan 31, 2023

BUY
$29.75 - $39.26 $20,021 - $26,421
673 New
673 $25,000

Others Institutions Holding AMLX

About Amylyx Pharmaceuticals, Inc.


  • Ticker AMLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,533,200
  • Market Cap $310M
  • Description
  • Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...
More about AMLX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.